Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

被引：0

作者：

Samoilova, Iuliia G. ^{[1
]}

Vaizova, Olga E. ^{[1
]}

Stankova, Anastasia E. ^{[1
]}

Matveeva, Mariia, V ^{[1
]}

Podchinenova, Daria, V ^{[1
,4
]}

Kudlay, Dmitry A. ^{[2
,3
]}

Borozinets, Anastasiia A. ^{[2
]}

Filippova, Tatyana A. ^{[1
]}

Grishkevich, Ivan R. ^{[1
]}

Partala, Anastasia, V ^{[1
]}

Gerasimova, Diana A. ^{[1
]}

机构：

[1] Siberia State Med Univ, Tomsk, Russia

[2] Sechenov First Moscow State Med Univ, Sechenov Moscow State Med Univ 1, Moscow, Russia

[3] Lomonosov Moscow State Univ, Moscow, Russia

[4] Inst Immunol, Natl Res Ctr, Moscow, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2024年 / 96卷 / 01期

关键词：

polymorphism; dipeptidyl peptidase-4 inhibitors; type 2 diabetes mellitus; GLP1R; DPP-4; KCNQ1; GLYCEMIC RESPONSE; EPIDEMIOLOGY; GENE;

D O I：

10.26442/00403660.2024.01.202553

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase -4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2, DPP -4, KCNQ1, KCNJ11, PNPLA3, PRKD1) are associated with the pharmacokinetic values and efficacy of dipeptidyl peptidase -4 inhibitors, which may be promising for personalizing the treatment of patients with type 2 diabetes mellitus.

引用

页码：63 / 67

页数：5

共 50 条

[31] The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
Yousefzadeh, Pegah
Wang, Xiangbing
JOURNAL OF DIABETES RESEARCH, 2013, 2013
[32] Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Ahren, Bo
EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (04) : 593 - 607
[33] Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
Mkele, Gail
JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA, 2015, 20 (01) : 64 - 66
[34] Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes
Jinsong Geng
Hao Yu
Yiwei Mao
Peng Zhang
Yingyao Chen
PharmacoEconomics, 2015, 33 : 581 - 597
[35] Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
Scheen, Andre J.
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 505 - 524
[36] Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes
Geng, Jinsong
Yu, Hao
Mao, Yiwei
Zhang, Peng
Chen, Yingyao
PHARMACOECONOMICS, 2015, 33 (06) : 581 - 597
[37] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
Deacon, Carolyn F.
Holst, Jens J.
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2047 - 2058
[38] Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
Mkele, Gail
SOUTH AFRICAN FAMILY PRACTICE, 2013, 55 (06) : 508 - 510
[39] Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
Mkele, Gail
SA PHARMACEUTICAL JOURNAL, 2013, 80 (02) : 17 - 19
[40] Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
Liao, Wen-Ling
Lee, Wen-Jane
Chen, Ching-Chu
Lu, Chieh Hsiang
Chen, Chien-Hsiun
Chou, Chun
Lee, I-Te
Sheu, Wayne H-H
Wu, Jer-Yuarn
Yang, Chi-Fan
Wang, Chung-Hsing
Tsai, Fuu-Jen
ONCOTARGET, 2017, 8 (11) : 18050 - 18058

← 1 2 3 4 5 →